BridgeMD
New treatment option for Congestion
Official title Optimization of Fluid Balance Guided by Bioelectrical Impedance Analysis in Patients Undergoing Continuous Renal Replacement Therapy in Critical Care
ClinicalTrials.gov ID: NCT06799910
What this study is testing
- What it's testing
- In critical care, hemodynamic instability often requires volume expansion to restore tissue perfusion, increasing fluid balance and TBW, factors associated with higher mortality. Excess fluid leads to organ dysfunction due to venous congestion, making fluid removal crucial.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age \> 18 years
- The patient was hospitalized in the intensive care unit of Amiens-Picardie University Hospital.
- Patient with an increase in fluid balance (TBW \> 5%)
- Patient receiving continuous veno-venous hemofiltration (CVVH) on a PrismaFlexR or PrisMaxR machine, initiated due to oliguria, potassium level \>...
- Hemodynamically stable patient with a mean arterial pressure (MAP) \> 65 mmHg for more than 4 hours with norepinephrine.
You likely can't join if
- Invalid BIA measurements
- Internal device powered by an electrical current (pacemaker, implantable cardioverter-defibrillator, neurostimulator)
- Cardiac arrhythmia (atrial fibrillation, atrial flutter) present at the inclusion
- Chronic dialysis patient
- Moribund patient
- The patient is on extracorporeal mechanical support
See the full eligibility criteria
- Age \> 18 years
- The patient was hospitalized in the intensive care unit of Amiens-Picardie University Hospital.
- Patient with an increase in fluid balance (TBW \> 5%)
- Patient receiving continuous veno-venous hemofiltration (CVVH) on a PrismaFlexR or PrisMaxR machine, initiated due to oliguria, potassium level \> 6.5 mmol/L, urea level \> 25 mmol/L, or creatinine \> 300 µmol/L and...
- Hemodynamically stable patient with a mean arterial pressure (MAP) \> 65 mmHg for more than 4 hours with norepinephrine.
- Signed consent to participate in the study by the patient or, if unconscious, their legal representative/next of kin.
- Invalid BIA measurements
- Internal device powered by an electrical current (pacemaker, implantable cardioverter-defibrillator, neurostimulator)
- Cardiac arrhythmia (atrial fibrillation, atrial flutter) present at the inclusion
- Chronic dialysis patient
- Moribund patient
- The patient is on extracorporeal mechanical support
- Hemorrhagic shock
- Pregnant woman
- Patient under guardianship or conservators.
The study team makes the final eligibility decision.
Where it's taking place
- Salouël, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Salouël, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.